Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% below its 5-year average of 2.07, near the high end of its 5-year range (-44.08–5.67).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% above its 12-month average of -2.56.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
-2.56
DEBT TO EQUITY RATIO AVG 3Y
2.36
DEBT TO EQUITY RATIO AVG 5Y
2.07
DEBT TO EQUITY RATIO AVG 10Y
1.41
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 531 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Market Cap
$7.36M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$7.13M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.20
5Y Avg
0.20
Market Cap
$7.07M
Debt to Equity Ratio
N/A
TTM Avg
0.03
3Y Avg
0.02
5Y Avg
0.01
Market Cap
$6.91M
Debt to Equity Ratio
0.06
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$6.88M
Debt to Equity Ratio
0.14
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$7.75M
Debt to Equity Ratio
N/A
TTM Avg
16.01
3Y Avg
9.73
5Y Avg
9.73
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| KALA BIO, Inc. (KALA) | $7.27M | 0.00 | -2.56 | 2.36 | 2.07 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.36M | 0.00 | 0.03 | 0.05 | 0.05 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.13M | 0.03 | 0.02 | 0.20 | 0.20 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.07M | N/A | 0.03 | 0.02 | 0.01 |
| Longeveron Inc. (LGVN)vs › | $7.51M | 0.06 | 0.11 | 0.16 | 0.47 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.91M | 0.06 | 0.01 | 0.01 | 0.01 |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | 0.14 | 0.05 | 0.03 | 0.02 |
| Aclarion, Inc. (ACON)vs › | $6.83M | 0.00 | 0.00 | 0.00 | 0.00 |
| HeartSciences Inc. (HSCS)vs › | $7.75M | N/A | 16.01 | 9.73 | 9.73 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | 1.71 | 0.66 | 0.41 | 0.34 |
Debt/Equity
0.00
Current Ratio
6.88
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | -3.46 |
| 2025-06-30 | -9.34 |
| 2025-03-31 | 5.67 |
| 2024-12-31 | 2.62 |
| 2024-09-30 | 5.40 |
| 2024-06-30 | 2.68 |
| 2024-03-31 | 5.49 |
| 2023-12-31 | 4.84 |
| 2023-09-30 | 3.22 |
| 2023-06-30 | 1.92 |
| 2023-03-31 | 1.42 |
| 2022-12-31 | 2.26 |
| 2022-09-30 | -44.08 |
| 2022-06-30 | -2.53 |
| 2022-03-31 | -15.28 |
| 2021-12-31 | 4.77 |
| 2021-09-30 | 1.74 |
| 2021-06-30 | 1.27 |
| 2021-03-31 | 0.93 |
| 2020-12-31 | 1.01 |
| 2020-09-30 | 0.95 |
| 2020-06-30 | 0.78 |
| 2020-03-31 | 0.71 |
| 2019-12-31 | 3.41 |
| 2019-09-30 | 2.35 |
| 2019-06-30 | 1.67 |
| 2019-03-31 | 1.23 |
| 2018-12-31 | 0.95 |
| 2018-09-30 | 0.36 |
| 2018-06-30 | 0.29 |
| 2018-03-31 | 0.25 |
| 2017-12-31 | 0.21 |
| 2017-09-30 | 0.20 |
| 2017-06-30 | -0.09 |
| 2017-03-31 | 0.43 |
| 2016-12-31 | -0.11 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | -1.69 |
